# US 2010/0166880 A1 · Method for treatment and diagnosis of glutamate dehydrogenase disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166880 A1
- Document ID: US20100166880A1
- Status: Published application
- Kind: A1
- Application number: 12/459,179
- Filed: 2009-06-25
- Published: 2010-07-01
- Earliest claimed: 2008-06-26
- Inventors: Andreas Plaitakis
- Web page: https://patentgrep.com/patent/US20100166880A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- C12Q 1/689: for bacteria
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods and compositions for diagnosis and treatment of neurodegenerative disorders are disclosed. The methods and compositions apply the discovery of the correlation between an hGDH2 gene polymorphism and the occurrence of atypical Parkinson's Disease.

## Claims

### Claim 1

A method for diagnosis of susceptibility to early onset Parkinson's disease comprising identifying a nucleic acid sequence exhibiting a polymorphism in GLUD2 gene, whereby that polymorphism comprises a substitution of guanine for tyrosine at position 1492.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the step of identifying such polymorphism comprises comparing the polymorphism in the GLUD2 gene to a normal wild type GLUD2 gene.

### Claim 3 (depends on 1)

A method according to claim 1, wherein the identifying step comprises the steps of obtaining a biological sample and testing that sample to identify a polymorphism in nucleic acid contained therein.

### Claim 4 (depends on 1)

A method according to claim 1, wherein the identifying step comprises the steps of obtaining a biological sample and testing that sample to identify a variant protein therein associated with the polymorphism.

### Claim 5 (depends on 3)

A method according to claim 3, wherein the identifying step comprises any of sequencing and probing the nucleic acid.

### Claim 6 (depends on 4)

A method according to claim 4, comprising identifying a variant hGDH2 protein in which alanine is substituted for serine in the 445 position.

### Claim 7 (depends on 5)

A method according to claim 5, wherein the identifying step comprises the step of amplifying a nucleic acid contained in the biological sample.

### Claim 8

A method for any of diagnosis and prediction of a neurodegenerative condition, wherein the method comprises the step of identifying a nucleic acid sequence exhibiting a polymorphism in an hGDH2 gene, whereby that polymorphism comprises a substitution of a whereby that polymorphism comprises a substitution of guanine for tyrosine at position 1492, and wherein the neurodegenerative condition is thereby diagnosed or predicted.

### Claim 9

A method for treating a patient with a disease linked to GDH disorders characterized by degeneration of neurons comprising administering a therapeutically effective amount of an agent selected from the group consisting of a small organic compound, a steroid, an estrogen, or an inorganic compound to a patient with the disease.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the agent modifies hGDH2 activity.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the agent modifies Glutamate levels.

### Claim 12

A method for postponing onset of a disease linked to GDH disorders characterized by degeneration of neurons comprising administering a therapeutically effective amount of an agent selected from the group consisting of a small organic compound, a steroid, an estrogen, or an inorganic compound to a patient with the disease.

### Claim 13 (depends on 12)

The method according to claim 12 wherein the agent modifies Glutamate levels.

### Claim 14 (depends on 12)

The method according to claim 12 wherein the agent modifies hGDH2 activity.

### Claim 15

A method for slowing progression of a disease linked to GDH disorders characterized by degeneration of neurons comprising administering a therapeutically effective amount of an agent selected from the group consisting of a small organic compound, a steroid, an estrogen, or an inorganic compound to a patient with the disease.

### Claim 16 (depends on 16)

The method of claim 16 wherein the agent modifies Glutamate levels.

### Claim 17 (depends on 15)

The method of claim 15 wherein the agent modifies hGDH2.
